Idiopathic Pulmonary Fibrosis  >>  pamrevlumab (FG-3019)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pamrevlumab (FG-3019) / FibroGen
NCT01262001: Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

Checkmark
Mar 2016 - Mar 2016: 
Checkmark In IPF
Feb 2016 - Feb 2016: In IPF
Checkmark Fibrosis
More
Completed
2
90
US
FG-3019, Pamrevlumab
FibroGen
Idiopathic Pulmonary Fibrosis
06/14
06/17
NCT01890265 / 2014-005658-20: Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Checkmark Presentation of HRCT and HRQoL results at ERS 2018
Sep 2018 - Sep 2018: Presentation of HRCT and HRQoL results at ERS 2018
Checkmark Presentation of HRCT and HRQoL results at ATS 2018
May 2018 - May 2018: Presentation of HRCT and HRQoL results at ATS 2018
Checkmark Completion of enrollment in P2 study 067
More
Completed
2
160
Europe, Canada, US, RoW
Pamrevlumab, Fully human recombinant immunoglobulin G (IgG), kappa monoclonal anti-body., FG-3019, Placebo, Sub-Study: Pirfenidone, Esbeiet, Sub-Study: Nintedanib, Ofev
FibroGen
Idiopathic Pulmonary Fibrosis
11/17
11/17

Download Options